Mark A. Moyad, MD, MPH, the Jenkins/Pokempner Director of Preventive & Complementary Medicine at the University of Michigan Medical Center, discusses new findings concerning supplements in prostate cancer treatment and the best natural alternatives.
Read More
Thomas E. Keane, MD, reviews the data supporting and opposing the advancement of chemotherapy into the metastatic castration-sensitive prostate cancer (mCSPC) disease state. He then discusses a current trial introducing chemotherapy in patients prior to androgen deprivation therapy (ADT).
Read More
John W. Davis, MD, debates the pros of using <20mg/mL as a threshold for the optimal nadir level of serum testosterone in prostate cancer patients treated with ADT.
Read More
Francisco G. La Rosa, MD, discusses how poor preparation of biopsy and prostatectomy specimens, as well as pathologists’ misreadings, can lead to significant discrepancies in the diagnosis of prostate cancer. He emphasizes the importance of reevaluation by in-house urologic pathologists of all outside specimens before evaluating treatment options for patients.
Read More
Deepak A. Kapoor, MD, FACS, discusses the history of efforts in the United States to transition healthcare toward a structure of value-based care. He then outlines major 2019 regulatory initiatives and how they will impact healthcare payments and the administrative burden for urologists.
Read More